Business, energy, technology, markets and global industry news from Business News Today

HER2-negative breast cancer

PharmaDeviceNews HER2-negative breast cancer
Representative image: Delcath Systems has dosed the first patient in the Phase 2 DELUMA trial evaluating HEPZATO for liver-dominant HER2-negative metastatic breast cancer.
Pharma & Biotech

Can HEPZATO move beyond uveal melanoma? Delcath begins major metastatic breast cancer test

Delcath has dosed the first patient in the DELUMA Phase 2 trial, testing HEPZATO for liver-dominant HER2-negative metastatic breast cancer.

Read More
Representative image of an oncology consultation, illustrating how Roche and Genentech’s giredestrant FDA priority review could reshape endocrine therapy decisions in early-stage breast cancer.
Pharma & Biotech

Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment

Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More
Representative image of breast cancer drug development, highlighting Avenzo Therapeutics’ ORION-1 trial of AVZO-023 and AVZO-021 in advanced HR+/HER2- metastatic breast cancer.
Pharma & Biotech

What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development

Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.

Read More
Representative image of advanced breast cancer research, reflecting Menarini Group’s ASCO 2026 elacestrant data and the growing focus on targeted treatment combinations for ER-positive, HER2-negative metastatic breast cancer.
Pharma & Biotech

ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance

Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.

Read More
Pharma & Biotech

Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy

Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.

Read More
Representative image: AI-powered digital pathology analysis could help reshape breast cancer risk stratification after ArteraAI Breast became the first FDA-cleared pathology-based breast cancer risk tool in the United States.
Medical Devices & Diagnostics

Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?

AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.

Read More
Pharma & Biotech

AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy

Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.

Read More
Representative image of a laboratory researcher reviewing spatial proteomics data for early-stage breast cancer, reflecting the clinical oncology focus behind the AidaBREAST assay and its potential role in recurrence risk and radiation therapy benefit assessment.
Medical Devices & Diagnostics

Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions

See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.

Read More
Medical Devices & Diagnostics

Delphi Diagnostics data challenges one-size-fits-all use of extended endocrine therapy in breast cancer

SABCS data suggests endocrine activity may predict who truly benefits from extended endocrine therapy. Here is what Delphi Diagnostics’ findings mean.

Read More